

Recro Pharma, Inc.
Form 4/A
March 20, 2017

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
SCP Vitalife Partners II LP

2. Issuer Name and Ticker or Trading Symbol
Recro Pharma, Inc. [REPH]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

(Last) (First) (Middle)
SUITE 190, 7 GREAT VALLEY PARKWAY

3. Date of Earliest Transaction
(Month/Day/Year)
03/14/2017

____ Director
____ Officer (give title below)
 10% Owner
____ Other (specify below)

(Street)
MALVERN, PA 19355

4. If Amendment, Date Original Filed(Month/Day/Year)
03/16/2017

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code V	Amount (A) or (D) Price		
Common Stock	03/14/2017		S ⁽¹⁾		16,328 D 8.0396 2,276,511 ⁽⁵⁾	D	
					⁽²⁾		
Common Stock	03/15/2017		S ⁽¹⁾		19,161 D 8.0122 2,257,350 ⁽⁵⁾	D	
					⁽³⁾		
Common Stock	03/16/2017		S ⁽¹⁾		9,488 D 7.9258 2,247,862 ⁽⁵⁾	D	
					⁽⁴⁾		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: Recro Pharma, Inc. - Form 4/A

the range set forth in footnote 3 to this Form 4.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$7.84 to \$8.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.

- (4)
- (5) This amendment corrects a previous clerical error to the "Amount of Securities Beneficially Owned Following Reported Transaction" contained in the Form 4 filed on March 16, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.